TARRYTOWN, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 second quarter and first half earnings release on Thursday, November 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.co ...

Prestige Consumer Healthcare Conference Summary Company Overview - Prestige Consumer Healthcare Inc. (NYSE: PBH) is a consumer healthcare company focused on over-the-counter medicines, helping consumers care for themselves daily [2][3] Key Business Segments - The company has a diversified portfolio of brands, including: - Monistat (50%+ market share in vaginal antifungal treatment) - Summer's Eve (40%+ market share in feminine hygiene) - Dramamine (60% market share in motion sickness) [4][5][10] Financial Performance - Over the last five years, total revenue grew by approximately 3.5%, with organic revenue growth in the range of 2% to 3% [9] - Adjusted earnings increased by about 9% annually, exceeding the long-term target of 6% to 8% [9] - The company maintains best-in-class EBITDA margins in the low 30s, contributing to strong free cash flow generation [7][22] Growth Strategy - The growth strategy is built on three pillars: 1. Investing in brand building to achieve 2% to 3% organic growth [6] 2. Maintaining a strong financial profile with an asset-light model and high free cash flow [7] 3. Reinvesting free cash flow into capital allocation for further growth and potential acquisitions [8][22] E-commerce Growth - E-commerce sales have increased from less than 1% to over 16% of total sales in the last five years, driven by investments in content and marketing [15][16] - The company aims to be channel-agnostic, ensuring products are available across various platforms [40] Innovation and Brand Building - The company introduces 3 to 5 new products annually, focusing on incremental innovations rather than large-scale launches [17] - Recent innovations include expanding the Dramamine brand to include non-drowsy options and nausea relief products [11][12] - The introduction of a maintain subline for Monistat allows for broader usage beyond acute treatment [19] International Expansion - The international segment accounts for about 16% of sales, with expected growth rates exceeding 5% [20] - Key brands include Hydralyte, a leading rehydration product in Australia, with plans for geographic expansion [20][21] Capital Allocation Strategy - The company prioritizes: 1. Investing in current brands for organic growth 2. M&A opportunities to consolidate consumer healthcare brands 3. Strategic share repurchases to offset dilution [23][24] - The company has a long-term leverage target of less than 3 times, currently at 2.4x [22] Challenges and Future Outlook - The Clear Eyes brand faced supply chain challenges, leading to a shortfall in revenue. The company is acquiring a critical supplier to enhance production capacity [26][32] - The long-term outlook remains positive, with expectations for continued free cash flow generation and strategic capital allocation to enhance shareholder value [26][27] Conclusion - Prestige Consumer Healthcare is well-positioned for sustainable growth through a diversified brand portfolio, strong financial management, and a focus on innovation and market expansion [27]

Core Insights - Prestige Consumer Healthcare Inc. is focusing on growth in its eye care business despite operational challenges in 2025 [1] - The acquisition of Pillar5 Pharma aims to resolve supply constraints and support long-term expansion in the eye care segment [2] - The company reported a 6.6% year-over-year revenue decline in Q1 2026 but showed momentum in other segments, including international OTC healthcare growth [3] Group 1: Company Strategy - Prestige Consumer Healthcare Inc. is taking strategic steps to secure growth in its eye care business amid operational challenges in 2025 [1] - The acquisition of Pillar5 Pharma is intended to address previous supply constraints and ensure reliable production for the Clear Eyes brand [2] Group 2: Financial Performance - The company experienced a 6.6% year-over-year revenue decline in Q1 2026 [3] - Despite the revenue decline, there was momentum in other business segments, including international OTC healthcare growth and improved gross margins [3] Group 3: Leadership Perspective - CEO Ron Lombardi emphasized that integrating Pillar5's capabilities strengthens the Clear Eyes franchise and enhances overall business resilience [3]

Company Overview - Prestige Consumer Healthcare focuses on niche categories where brands can compete successfully over the long term [2] - The company emphasizes the breadth and depth of its consumer connections through its product offerings [2] Product Impact - The company sells enough Clear Eyes and TheraTears to treat 12 billion irritated eye occasions annually [2] - It addresses 650 million sore and dry throat occasions each year [2] - The BC and Goody's powdered analgesic brands help treat approximately 17 million pain occasions weekly, including hangovers [2] - Monistat assists in treating about 8 million vaginal yeast infections annually [2]

Financial Data and Key Metrics Changes - The company reported a free cash flow of approximately $242 million for the previous year, with an outlook for this year exceeding $245 million [10][48] - The five-year compound annual growth rates (CAGRs) showed revenue growth of about 3.5%, organic growth of 2.5%, and earnings per share (EPS) growth of nearly 9% [12] Business Line Data and Key Metrics Changes - The largest category for the company is gastrointestinal (GI) health, followed by women's health, eye and ear care, skin care, and analgesics [4] - The company has a diverse portfolio that allows it to manage fluctuations in illness levels effectively, with brands performing variably based on market conditions [6][51] Market Data and Key Metrics Changes - The company's e-commerce sales have grown significantly, increasing from about 4% of total sales five years ago to approximately 16% at the end of the last fiscal year, with two-thirds of that coming from Amazon [25] - The international business, particularly in Australia, has been growing in the mid-teens on average over the last five years, exceeding long-term expectations [37] Company Strategy and Development Direction - The company focuses on niche categories where brands can compete successfully over the long term, emphasizing brand building and consumer insights [2][8] - The management plans to utilize free cash flow for mergers and acquisitions (M&A), share repurchases, and maintaining a strong balance sheet [41][42] Management's Comments on Operating Environment and Future Outlook - Management acknowledged capacity constraints affecting the Clear Eyes brand but expressed confidence in addressing these issues with new suppliers coming online [47][48] - The company maintains its free cash flow outlook despite adjustments to top-line expectations, indicating resilience in its business model [48] Other Important Information - The company has a strong financial profile characterized by low capital expenditures and a variable cost model, which supports consistent free cash flow generation [40] - The management highlighted the importance of consumer insights in driving product innovation and brand growth [53] Q&A Session Summary Question: What are the kind of valuations the company is seeing? - The company has not observed a meaningful shift in valuations for the brands it targets, emphasizing its competitive advantages over private equity in terms of cost of capital and operational sophistication [59] Question: How does the company view the shift in retail channels? - Management noted that channel shifts are not new and emphasized the importance of adapting marketing strategies to support retail partners across various channels, including drugstores and e-commerce [61][62]

Financial Data and Key Metrics Changes - The company reported a free cash flow of approximately $242 million for the previous year, with an outlook of over $245 million for the current year, indicating a strong financial profile and consistent cash generation [9][48]. - The five-year compound annual growth rates (CAGRs) showed revenue growth of about 3.5%, organic growth of 2.5%, and earnings per share (EPS) growth of nearly 9% [11]. Business Line Data and Key Metrics Changes - The company operates in several categories, with gastrointestinal (GI) being the largest, followed by women's health, eye and ear care, skin care, and analgesics [4][5]. - The company has a diverse portfolio that allows it to manage fluctuations in illness levels effectively, with brands performing variably based on market conditions [6][10]. Market Data and Key Metrics Changes - The e-commerce segment has grown significantly, with online sales increasing from about 4% of total sales five years ago to approximately 16% by the end of the last fiscal year, with two-thirds of that attributed to Amazon [24][25]. - The international business, particularly in Australia, has been growing in the mid-teens, exceeding long-term expectations of mid to high single-digit growth [36]. Company Strategy and Development Direction - The company focuses on investing in niche categories where brands can compete effectively, emphasizing a brand-building playbook that includes understanding consumer insights and agile marketing strategies [2][12]. - The company aims to utilize its strong cash flow for mergers and acquisitions (M&A), share repurchases, and maintaining a low leverage ratio, with a preference for M&A as the primary use of cash [41][42]. Management's Comments on Operating Environment and Future Outlook - Management acknowledged capacity constraints affecting certain brands but expressed confidence in addressing these issues through new supplier agreements and operational adjustments [46][48]. - The company maintains its free cash flow outlook despite adjustments to top-line revenue expectations, indicating resilience in its financial performance [48]. Other Important Information - The company has a disciplined approach to M&A, focusing on acquiring brands with leading positions in niche categories, and has significant acquisition capacity without returning to previous high leverage levels [44][45]. - The company has successfully launched several new products, including Dramamine advanced herbals for kids and Summer's Eve whole body deodorant, which have performed well in their respective markets [31][33]. Q&A Session Summary Question: What are the kind of valuations the company is seeing in the market? - The company has not observed a meaningful shift in valuations for the types of brands it seeks, emphasizing its competitive advantages over private equity in terms of cost of capital and operational sophistication [58][59]. Question: How does the company view the shift in retail channels from traditional drugstores to clubs and retailers? - The company has adapted to channel shifts by developing unique programs for each retail partner and remains committed to supporting brands in the drug channel while also leveraging opportunities in e-commerce and other retail formats [60][62].

Financial Performance & Strategy - FY25 revenues reached $1,137.8 million[69] - The company achieved a 5-year revenue CAGR of 34%[17,69] - Adjusted EPS 5-year CAGR was +88%[17] - Organic revenue 5-year CAGR was +24%[17,69] - Adjusted FY25 Free Cash Flow reached $243291 thousand[49,75] - Net leverage was significantly reduced to 24x[49] - The company anticipates approximately $1 billion total Free Cash Flow over the next four years[51] E-commerce & International Expansion - E-commerce as a percentage of net sales has increased +4x from approximately 4% in FY19 to approximately 16% in FY25[33] - International revenue accounts for approximately 16% of Prestige Net Sales in FY25[45] FY26 Outlook - Expected revenue for FY26 is projected to be between $1,100 to $1,115 million[59] - Projected FY26 Non-GAAP Free Cash Flow is $245 million[59,77]

Group 1 - Prestige Consumer Healthcare Inc. will present at the Barclays Global Consumer Staples Conference on September 4, 2025, at 12:45 p.m. ET [1] - Interested parties can access a live webcast of the event on the company's website under the "Investors" section [1] - A replay option will be available on the company's website for those unable to participate in the live webcast [1] Group 2 - Prestige Consumer Healthcare is a leading consumer healthcare products company with sales in the U.S., Canada, Australia, and other international markets [2] - The company's diverse portfolio includes brands such as Monistat®, Summer's Eve®, BC®, Goody's®, Clear Eyes®, TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic®, Luden's®, Compound W®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, Debrox®, Gaviscon®, Hydralyte®, and Fess® [2]

Financial Data and Key Metrics Changes - The company recorded normalized EBITDA of $11,200,000, representing a $13,000,000 improvement compared to the previous corresponding period (PCP) [10] - Group revenue increased by 6% to $261,400,000, with gross profit rising to $137,000,000, up from $126,000,000, resulting in a gross profit margin of 52.4% [19][20] - The group achieved a record number of rolling twelve-month cash actives at 295,800, marking a significant milestone [10] Business Line Data and Key Metrics Changes - In Australia, revenue reached $218,500,000, a 3% increase from the PCP, with gross profit also at a record of $114,500,000, up 2% [11] - The Australian business achieved a statutory segment EBITDA of $30,100,000, reflecting a 12% increase from the PCP [13] - In Canada, net win grew by 26% to $43,000,000, with sports betting net win at $17,000,000, up 11%, and iGaming net win at $26,000,000, increasing by 39% [16][17] Market Data and Key Metrics Changes - The Australian wagering market experienced a material decline, estimated at around 7% for FY 2025, despite PointsBet gaining market share [26][27] - The Canadian market showed strong growth momentum, with a significant increase in cash active clients by 30% to 58,004 [17][18] Company Strategy and Development Direction - PointsBet is focused on enhancing its mass market recreational segments in both Australia and Canada to create a more diversified and sustainable revenue base [10] - The company is actively encouraging reforms in the wagering industry regarding advertising, aiming for a sustainable framework that leverages digital and social media platforms [14][15] Management's Comments on Operating Environment and Future Outlook - Management noted that the Australian market has not grown at a net win level, indicating challenges ahead but expressed hope for a return to growth based on recent positive trends [26][27] - The company anticipates continued market growth tailwinds in the regulated Canadian market, particularly with Alberta expected to go live [18] Other Important Information - PointsBet's board has recommended shareholders accept the MiXi Australia takeover offer, which provides a 50.6% cash premium over the share price prior to the announcement [4][6] - The company paid $115,300,000 in taxes and fees to Australian governments and sports bodies, representing 47.9% of its net win for the year [14] Q&A Session Summary Question: What is the estimated decline in the Australian wagering market for FY 2025? - Management agreed with estimates of around 7% decline, noting that the last quarter showed some positive margins for operators, indicating potential for future growth [26][27] Question: What are the next steps if MiXi exceeds 50.1% ownership? - If MiXi achieves over 50.1% before the offer closes, it will trigger a two-week extension for the offer [28][29]

Financial Data and Key Metrics Changes - The company recorded normalized EBITDA of $11.2 million, a $13 million improvement compared to the previous corresponding period (PCP) [10] - Group revenue increased by 6% to $261.4 million, with gross profit rising to $137 million, up from $126 million, resulting in a gross profit margin of 52.4% [18][19] - The gross profit margin decreased by 0.4 percentage points compared to the PCP [19] Business Line Data and Key Metrics Changes - In Australia, revenue reached a record $218.5 million, up 3% from the PCP, with gross profit also at a record $114.5 million, up 2% [11] - The Australian gross win margin improved by 1.8 percentage points to 13.6%, while the net win margin increased by 1 percentage point to 10.4% [12] - In Canada, net win grew by 26% to $43 million, with sports betting net win at $17 million, up 11%, and iGaming net win at $26 million, up 39% [15][16] Market Data and Key Metrics Changes - The Australian wagering market experienced a material decline, estimated at around 7% for the year, despite PointsBet gaining market share [26] - The Canadian market showed strong turnover growth, maintaining PointsBet's net win market share [15] Company Strategy and Development Direction - PointsBet aims to diversify its revenue base by focusing on mass market recreational segments in both Australia and Canada [10] - The company is actively encouraging reforms in the wagering industry regarding advertising to leverage digital and social media platforms [14] Management Comments on Operating Environment and Future Outlook - Management noted that the Australian market has not grown at a net win level, but there are signs of improvement in the last quarter [26] - The company expects continued market growth tailwinds in the regulated Canadian market [17] Other Important Information - PointsBet paid $115.3 million in taxes and fees to Australian governments and racing bodies, representing 47.9% of its net win for the year [14] - The company had $22.7 million in corporate cash and net assets of $6 million as of June 30, 2025 [21] Q&A Session Summary Question: What is the estimated decline in the Australian wagering market for FY 2025? - Management agreed with estimates of around 7% decline, noting that the last quarter showed some positive margins for operators [26] Question: What are the next steps if MiXi increases above 50.1%? - If MiXi goes through 50.1% before the offer closes, it would trigger a two-week extension for the offer [28][29]